lobbying_activities: 2957264

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2957264	a25220b8-283b-4f1c-99d6-5ea9eb4de71d	Q1	RED+BLUE STRATEGIES	400693064	PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)	2023	first_quarter	PHA	S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission. S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest. Issues related to prescription drug supply chain integrity and transparency. Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.	Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE	70000		0	0	2023-04-11T15:37:56-04:00